title: Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives.
abstract: The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.
authors.affiliation: Department of Gastrointestinal Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Davidson
authors.affiliation: Department of Gastrointestinal Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
authors.forename: Naureen
authors.initials: N
authors.lastname: Starling
keywords: HER2; gastric cancer; immunohistochemistry; in situ hybridization; trastuzumab